Career Strategy
Building a U.S. Career as a Polish biotech CEO — April 2026
Everything you need to know about the latest changes and how they affect your O-1 strategy.
The O-1A Standard for Executive Biotech Professionals
Biotech executives seeking O-1A classification face a structurally distinct evidentiary challenge compared to research scientists or academic practitioners. The O-1A criteria in 8 C.F.R. § 214.2(o)(3)(iii) were developed with reference to the traditional markers of scientific distinction — prizes, publications, citations, peer review service, high salary relative to peers, and critical or essential role in distinguished organizations. A chief executive or managing director of a biotech company may have a thin publication record and no academic awards, while simultaneously commanding a salary well above industry norms, leading an organization with recognized market standing, having made contributions of documented significance to the company's scientific and commercial trajectory, and holding a visible industry profile through speaking invitations, board appointments, and media coverage.
The evidentiary strategy for biotech executives is to build the case around the criteria that most naturally reflect executive distinction rather than research distinction — and to frame the research-adjacent contributions the executive has made in research-consistent criterion language where the record supports it. Many biotech executives began as researchers and carry publications and citation records from earlier career phases; those credentials remain relevant and should be documented even if the current role is exclusively executive. The O-1A regulation evaluates the beneficiary's career record, not only the proposed U.S. role, which means a strong early-career research record combined with a strong current executive record creates a more robust evidentiary picture than either phase alone.
Polish biotech executives navigating this classification in 2026 face an additional practical challenge: Poland's biotech sector has grown significantly over the past decade, with recognized clusters in Warsaw, Krakow, and Wroclaw and EU-funded research programs that have produced internationally recognized output, but the sector's international visibility remains lower than comparable sectors in Western Europe or the United States. Documenting the significance of contributions made within the Polish biotech ecosystem requires translating sector-specific context for adjudicators who may not be familiar with Polish biotech's institutional landscape, funding structures, or benchmark companies.
Critical Role in Distinguished Organizations
The critical role criterion is typically the strongest criterion for biotech executives because executive leadership by definition involves critical or essential responsibility for organizational outcomes. The criterion requires documentation of distinguished reputation for the organizations the beneficiary has led or contributed to in a critical capacity. For a biotech company, distinguished reputation can be established through equity raise milestones, regulatory approvals, clinical stage progression, partnership agreements with recognized pharmaceutical companies, patent portfolio scope, and press coverage in recognized biotech trade publications such as FierceBiotech, BioCentury, Endpoints News, and STAT.
Polish biotech companies that have raised EU Horizon funding, participated in EIC Accelerator programs, or attracted co-investment from recognized international venture funds have a documented institutional profile that can be presented as evidence of distinguished organizational reputation. A company that has received EIC Accelerator funding, for example, has passed a competitive selection process administered by a recognized European innovation program — a fact that can be documented through official program records and explained as the functional equivalent of peer selection by an expert jury. The petition should not assume that the adjudicator knows what EIC Accelerator funding means for company quality; the cover letter should explain it.
The beneficiary's specific role in building the organization's distinguished standing is as important as the organization's reputation itself. A chief executive who led the company through a Series B raise, a pivotal clinical trial result, or a partnership agreement with a major pharmaceutical company has demonstrable individual contribution to the organization's trajectory. The petition should document not just that these events happened, but that the beneficiary's leadership was causally connected to them — through board resolutions, press releases quoting the CEO's role, investor documentation, and expert letters from board members or co-founders who can speak to the executive's specific contribution.
High Salary and Executive Compensation Evidence
Biotech CEO compensation in Europe and the United States varies substantially by company stage, funding level, therapeutic area, and geography. The relevant comparison population for a Polish biotech CEO is not the median compensation for all CEOs globally or even all biotech CEOs globally — it is the compensation of CEOs at comparable-stage biotech companies in the relevant geographic and market context. BLS OEWS data for chief executives provides a broad national baseline; industry compensation surveys from organizations like Radford, Pearl Meyer, or the Biotechnology Innovation Organization provide more sector-specific data that better reflects the biotech CEO compensation landscape.
Executive compensation in biotech frequently includes equity components — stock options, restricted stock units, or carried interest — that are not reflected in base salary alone. The petition should document the total compensation package, including equity, and explain the methodology for valuing equity components where the valuation is not fixed. For a company that has completed an equity raise at a documented valuation, the equity compensation can be valued at the round price; for a pre-revenue company, the equity is more difficult to value with precision. The petition should present the best available valuation methodology rather than omitting equity from the compensation analysis.
The high salary criterion is not the strongest criterion for most biotech executives, but it contributes to the overall picture when the compensation documentation is specific and the comparison population is well-selected. Practitioners should obtain the most relevant compensation benchmarks available — Radford Biotech Survey data, where accessible, provides industry-specific percentile data by company size and stage that is more probative than BLS broad-occupational data for senior biotech executives. The cover letter should explain the benchmark selection and the percentile analysis explicitly, so the adjudicator understands why the selected comparison supports the high salary conclusion.
Original Contributions and Published Scientific Work
Biotech executives who began their careers as researchers may have publication records, patent portfolios, or citation histories from earlier career phases. These credentials should be documented in the O-1A petition even if the current role is exclusively executive, because the original contributions criterion evaluates contributions to the field over the beneficiary's career, not only in the proposed role. A chief executive with twenty publications, two hundred citations, and three issued patents from a prior research career has a substantially stronger original contributions record than a career executive who entered the industry through business development without a research background.
For executives whose research contributions were primarily made in Poland or other European contexts, the petition should contextualize the contributions relative to both the Polish and the international scientific communities. A publication in a peer-reviewed journal indexed in PubMed or Web of Science is accessible and evaluable regardless of the author's institutional affiliation; a publication in a Polish-language journal with limited international indexing requires more explanation of its field significance. The petition should prioritize international publications and citations for criterion documentation and supplement with domestic contributions where the domestic record adds material evidentiary weight.
Patent portfolios require separate documentation strategy from publication records. A patent issued by the European Patent Office, the United States Patent and Trademark Office, or another major patent authority represents a documented original contribution — the patentability determination reflects that a government authority found the invention novel and non-obvious. The petition should document each patent with the patent number, issuing authority, filing and grant dates, and a brief lay-language description of the invention's significance to the relevant biotech field. Expert letters from researchers or executives familiar with the technical domain can explain the commercial and scientific significance of the patented technology for adjudicators without specialized technical backgrounds.
Industry Speaking, Media, and Membership Recognition
Biotech CEOs who participate as speakers or panelists at recognized industry conferences, advisory board members for sector associations, or invited contributors to recognized industry publications have evidence for the critical role and recognition criteria that does not require publication or award documentation. Conference invitations from recognized events — Bio International Convention, JP Morgan Healthcare Conference, Biotech Showcase, or sector-specific European conferences — represent peer selection by recognized industry institutions. The petition should document each speaking or participation invitation with the event program, the beneficiary's session description, and — where available — coverage of the event in recognized trade publications.
Media coverage of the beneficiary's professional work, company announcements, and industry commentary in recognized biotech trade publications and business media contributes to the recognition criterion. Coverage in FierceBiotech, BioCentury, Endpoints News, STAT, Forbes, or comparable outlets is more probative than coverage in general business press without sector focus, because trade publication coverage demonstrates recognition by an audience of industry practitioners rather than a general readership. The petition should include the full text of relevant coverage excerpts, identify the publication and its readership profile, and highlight the specific language that speaks to the beneficiary's individual recognition rather than general company coverage.
Membership in recognized professional organizations — the Biotechnology Innovation Organization, European Federation of Pharmaceutical Industries and Associations affiliate bodies, relevant Polish biotechnology associations — documents the beneficiary's professional standing within the recognized infrastructure of the field. The petition should distinguish between membership in organizations that anyone can join and membership in organizations whose admission reflects professional standing or selection. Advisory board appointments, steering committee roles, and elected positions within recognized industry organizations are more probative than general membership enrollment and should be documented with appointment letters, committee records, and evidence of the organization's selection process where available.
Building the U.S. Career Transition Strategy
O-1A classification requires not only documentation of the beneficiary's extraordinary ability but also a qualifying offer of employment or engagement from a U.S. petitioner, or a demonstrated need for the beneficiary's services in the United States. For a Polish biotech CEO seeking to establish a U.S. presence, the U.S. petitioner may be a subsidiary or affiliated entity of the existing company, a U.S. partner company with which the beneficiary has an existing relationship, or a U.S. entity that has recruited the beneficiary for a new executive role. The structure of the U.S. engagement affects both the petition's classification arguments and the beneficiary's practical path to building a U.S. career.
Biotech executives who seek O-1A classification as an intercompany transferee — using the L-1A classification rather than O-1A — face a different set of criteria. L-1A classification requires a qualifying relationship between the foreign and U.S. entities and a qualifying managerial or executive role in both; it does not require a showing of extraordinary ability. Practitioners should assess both classification options and advise the beneficiary on which better fits both the current evidentiary record and the long-term immigration strategy, since O-1A does not require a qualifying corporate relationship and is more portable across employers than L-1A.
The long-term career strategy for a Polish biotech executive in the United States typically includes a path toward EB-1A or EB-1C permanent residence. EB-1A extraordinary ability green card requires the same underlying showing as O-1A nonimmigrant status, and a strong O-1A record — particularly one built with the USCIS criteria in mind — translates well to the EB-1A evidentiary standard. EB-1C requires a qualifying multinational managerial or executive role and is the standard path for executives transferred from foreign parent companies. Practitioners advising biotech executives should be explicit about which green card classification each client is likely to pursue and build the nonimmigrant record accordingly.